20.24
-0.69(-3.30%)
Currency In USD
| Previous Close | 20.93 |
| Open | 21.13 |
| Day High | 21.13 |
| Day Low | 20.12 |
| 52-Week High | 36.37 |
| 52-Week Low | 15.47 |
| Volume | 204,700 |
| Average Volume | 337,421 |
| Market Cap | 742.71M |
| PE | -5.38 |
| EPS | -3.76 |
| Moving Average 50 Days | 22.02 |
| Moving Average 200 Days | 24.33 |
| Change | -0.69 |
If you invested $1000 in ArriVent BioPharma, Inc. Common Stock (AVBP) since IPO date, it would be worth $1,012 as of July 30, 2025 at a share price of $20.24. Whereas If you bought $1000 worth of ArriVent BioPharma, Inc. Common Stock (AVBP) shares 6 months ago, it would be worth $695.77 as of July 30, 2025 at a share price of $20.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
GlobeNewswire Inc.
Jul 21, 2025 12:00 PM GMT
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVB
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jul 02, 2025 3:15 AM GMT
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jul 01, 2025 8:05 PM GMT
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced tha